Press Releases

November 9, 2020 at 4:01 PM EST

Summary Toggle Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data

Investor conference call at 4:30 p.m. ET today SAN DIEGO --(BUSINESS WIRE)--Nov. 9, 2020-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and

PDF Version
November 9, 2020 at 7:00 AM EST

Summary Toggle Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore

Based on interim Phase 1/2 results, a single 7.5 µg dose of ARCT-021, along with prime-boost regimens are selected to advance into later stage global clinical trials Seroconversion in majority of participants receiving doses in the range of 5 µg to 7.5 µg; Geometric Mean Titer (GMT) levels for

PDF Version
November 4, 2020 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO --(BUSINESS WIRE)--Nov. 4, 2020-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
October 30, 2020 at 9:00 AM EDT

Summary Toggle Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020

SAN DIEGO --(BUSINESS WIRE)--Oct. 30, 2020-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
October 6, 2020 at 2:30 AM EDT

Summary Toggle Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate

Recipharm, a leading contract development and manufacturing organisation (CDMO) has entered into an agreement with Arcturus Therapeutics, a leading U.S. based clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities

PDF Version
October 5, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

LUNAR® lipids undetectable in plasma 48 hours following drug administration ARCT-810 well tolerated at doses up to 0.3 mg/kg, 0.4 mg/kg cohort to be completed in Q4 Initial dosing of OTC-deficient patients at a U.S. clinical site expected in Q4 SAN DIEGO --(BUSINESS WIRE)--Oct.

PDF Version
October 1, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference

SAN DIEGO --(BUSINESS WIRE)--Oct. 1, 2020-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
September 8, 2020 at 8:30 AM EDT

Summary Toggle Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
September 4, 2020 at 10:31 AM EDT

Summary Toggle Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate

Encouraging preclinical results demonstrate a strong antibody and cellular immune response and 100% protection against SARS-CoV-2 infection following a single vaccination Clinical study remains on track, initial data readout expected Q4 2020 SAN DIEGO , Sept.

PDF Version
August 18, 2020 at 9:00 AM EDT

Summary Toggle Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health

SAN DIEGO , Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version